Evidence map›Paper›PMID 39948230›Full record

ArticleDiscover oncology2025

Construction of regulatory T cells specific genes predictive models of prostate cancer patients based on machine learning: a computational analysis and in vitro experiments.

Zhengrong Zhou, Chaozhao Liang

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhengrong ZhouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. liangcz0320@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiseases are often caused by multiple factors, regulatory T cells specific genes (RTSGs) have been shown to be associated with cancer, however, their role in prostate cancer (PRAD) has not been fully explored.

methodsRTSGs associated with PRAD prognosis were identified using Cox regression analysis and LASSO analysis. Furthermore, a prognostic model was constructed in PRAD based on the 4 RTSGs, and its biological function were analyzed. We evaluated the differences in tumor immune microenvironment based on prognostic signature. Finally, cell experiments confirmed the function of synaptonemal complex protein-2 (SYCP2) in PRAD cells.

resultsThe prognostic value of RTSGs in PRAD patients has been comprehensively analyzed for the first time and identified four RTSGs with prognostic values. A prognosis risk model was constructed based on four RTSGs and its prognostic value was validated on an independent external PRAD dataset. In PRAD patients, this prognostic feature is an independent risk factor and was significantly correlated with clinical feature information of PRAD patients. This feature is also related to the immune microenvironment of PRAD. Cell experiments have confirmed that SYCP2 regulates the apoptosis and cycle progression of PRAD cells significantly. Therefore, SYCP2 may become an important regulatory factor in the progression of PRAD by participating in intracellular functional regulation.

conclusionsThis research provides a fundamental theoretical basis for improving the diagnosis and treatment of PRAD in clinical practice.

Indexed as

C4-2 cellsImmunePrognosisProstate cancerRegulatory T cells

Identifiers

PMID39948230
PMCPMC11825432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.